Background {#Sec1}
==========

Intracerebral hemorrhage (ICH) is a major cause of death and disability, with an incidence rate of 24.6 per 100,000 person-years and a fatality rate of 40%. After such event, only 12--39% of patients regain independence \[[@CR1]\]. Contrary to ischemic stroke, medical care for ICH remains mostly supportive, and few interventions clearly demonstrated benefit in this population \[[@CR2], [@CR3]\]. Several prognostic tools have been proposed for mortality and functional outcome prediction in ICH. These tools are potentially useful for ascertaining prognosis, facilitating communication between clinicians, characterizing and selecting patients for interventions, and for benchmarking purposes in healthcare delivery \[[@CR2], [@CR4]\].

The aim of this study was to systematically identify, assess and review the methodological conduct and reporting of studies deriving prognostic tools for the risk of death and/or functional recovery after ICH and to evaluate their overall discrimination according to the method of derivation and type of outcome.

Methods {#Sec2}
=======

We have designed, developed and reported our systematic review and meta-analysis in accordance with recommendations from the Cochrane Prognosis Methods Group \[[@CR5]\] and the PRISMA \[[@CR6]\] and MOOSE \[[@CR7]\] guidelines. For this purpose, we searched PubMed, ISI Web of Knowledge, Scopus, and CENTRAL for all studies reporting the derivation of prognostic tools for predicting death and/or functional recovery after non-traumatic ICH, using the broad and sensitive search query reported Additional file [1](#MOESM1){ref-type="media"}. The search included articles from database inception to 15th September 2016, with additional articles identified from reference checking. No language restrictions were applied. There is no protocol available.

Study selection and inclusion criteria {#Sec3}
--------------------------------------

Articles were included if they met the following criteria: 1) were human studies; 2) were original articles; 3) were adult studies (≥ 18 years); 4) did not consist of case reports/ case series; 5) enrolled non-traumatic ICH patients; 6) were prognostic studies; 7) described the application of a prognostic tool; and 8) were derivation studies. Studies involving traumatic and/or extra-axial bleedings were excluded. Study selection was performed using a two-step process. In the first step (screening), all abstracts were reviewed by two authors independently applying the inclusion criteria. This process was repeated in the second step again by two authors working independently, applying the same criteria to the full text of remaining studies. Disagreements were resolved by consensus.

Quality assessment, data extraction, analysis and reporting {#Sec4}
-----------------------------------------------------------

To inform quality assessment and data extraction from individual studies, two reviewers independently applied a spreadsheet based in the CHARMS checklist \[[@CR5]\] to the included studies, gathering information on the following aspects of prognostic tool derivation: 1) population, sampling and source of data; 2) outcome timing and definition; 3) number and type of predictors; 4) number of patients and events 5) handling of missing data; 6) method for tool derivation and 7) prognostic tool performance.

Prognostic tool performance was evaluated by determining its discriminatory capacity, i.e., its ability to determine which patients will suffer the outcome of interest. As a measure of this, we retrieved the c-statistic along with its 95% confidence interval (CI). For studies not reporting any of these parameters, we obtained them by recreating the receiver operating characteristic (ROC) curve from reported probability distributions; for studies reporting the c-statistic but not its confidence interval, we calculated the later using the method reported by Hanley and McNeil \[[@CR8]\], where the number of outcomes was available. Standard errors were derived from the respective CIs.

Given the fact that some authors derived more than one tool from the same sample population, we pooled c-statistics using robust variance estimation (RVE) to account for dependent effects, according to Tanner-Smith et al. \[[@CR9]\]. Specifically, we assumed correlated effect sizes and used a random effects model with inverse variance weights to estimate the overall mean c-statistic and mean c-statistics for mortality prediction tools, functional outcome prediction tools, logistic regression based tools, and machine learning algorithms. Univariate meta-regression was used to compare these groups and *p* values \< 0.05 were considered significant. Due to the nature of the meta-analytical technique used, heterogeneity statistics such as Q-statistic and I-square are not recommended, according to Tanner-Smith et al. \[[@CR9]\]. However, the I2 statistic is reported for illustrative purposes. Statistical analysis was performed using specific macros \[[@CR9]\] designed for R and SPSS® statistics v 24.0.

Results {#Sec5}
=======

Figure [1](#Fig1){ref-type="fig"} depicts the study selection procedure. The search query retrieved 15,613 references: after the screening step, there were 263 references left for full text review. The second step removed an additional 207 references, leaving us with 56 studies reporting the derivation of at least one prognostic tool. Three additional studies were identified through reference check, which led to the final number of 59 studies involving 48,133 patients. Nine studies reported the derivation of more than one prognostic tool, so the total number of prognostic tools analyzed was 72. The summary description of these tools is depicted in Table [1](#Tab1){ref-type="table"}.Fig. 1Study selection flow chartTable 1Summary description of prognostic toolsAuthorYearPopulationToolTimingVariablesAUC (SE)Mortality prediction tools Alsina \[[@CR24]\]2014Supratentorial ICH not submitted to surgeryEquation30 daysIVH, hematoma size, and midline shift.0·933 (0·029) Berwaerts \[[@CR41]\]2000Oral anticoagulant related ICHEquationDischargeHematoma diameter and CT signs of ischemia.-- Bhatia \[[@CR65]\]2013Primary ICHEquationDischargeGCS, hematoma size, IVH,and ventilatory requirement.0·822 (0·033) Broderick \[[@CR44]\]1993Spontaneous ICHEquation30 daysGCS, hematoma size.0·805 (0·036) Broderick´ \[[@CR44]\]1993Spontaneous ICHEquation30 daysHematoma size, IVH volume, GCS, and surgery.-- Celik \[[@CR68]\]2014Spontaneous ICHANN10 daysAge, gender, hypertension, diabetes, smoking, mean blood pressure, Scandinavian Stroke Scale score, pulse pressure, localization of hemorrhage (including infratentorial), volume of hemorrhage, ventricular drainage, and midline shift.-- Cerillo \[[@CR21]\]1981Operated supratentorial ICHEquationDischargeAge, mode of onset, site of hemorrhage, level of consciousness, time from onset to surgery, congestive heart failure/coronary artery disease, and diabetes/uremia.0·893 (0·033) Chen \[[@CR45]\]2011Nontraumatic ICHScoreDischargeGCS, hematoma volume, IVH, and diabetes.0·867 (0·027) Chiu \[[@CR61]\]2016Spontaneous ICHCART+SVM30 daysGCS, hematoma size.-- Chuang \[[@CR63]\]2009Spontaneous ICHScore30 daysAge, GCS, hypertension, glucose and dialysis dependency.0·890 (0·026) Edwards \[[@CR28]\]1999Supratentorial ICHANNDischargeGender, race, hydrocephalus, mean arterial pressure, pulse pressure, GCS, IVH, hematoma size, location (thalamic, basal, lobal), cisternal effacement, pineal shift, hypertension, diabetes, and age.0·984 (0·020) Edwards´ \[[@CR28]\]1999Supratentorial ICHEquationDischargeHydrocephalus, GCS, gender, pineal shift0·919 (0·043) Fogelholm \[[@CR31]\]1997Supratentorial ICHEquation28 daysConsciousness, mean arterial pressure, subarachnoid spread, midline shift, glucose, and vomiting.-- Frithz \[[@CR12]\]1976ICH patients \< 70 yearsDecision treeDischargeConsciousness, diastolic blood pressure.0·943 (0·024) Galbois \[[@CR38]\]2013Spontaneous comatose ICH not submitted to surgeryScoreICU stayBrainstem reflexes, swirl sign.0·850 (0·050) Galbois´ \[[@CR38]\]2013Spontaneous comatose ICH not submitted to surgeryScoreICU stayCorneal reflexes, swirl sign.0·840 (0·051) Grellier \[[@CR66]\]1983Spontaneous ICHScore2 daysAge, gender, consciousness (normal, changed, coma), CV risk factors (alcohol, tobacco, hypertension, dyslipidemia, CV disease), and ICH location (infratentorial, thalamic, internal capsule, oval center, lobar).-- Hallevi \[[@CR34]\]2009Primary ICH with IVHScoreDischargeGCS, total volume (ICH + IVH).0·840^a^ Hemphill \[[@CR48]\]2001Nontraumatic ICHScore30 daysAge, ICH volume, infratentorial ICH, GCS, and IVH.0·920 (0·020) Ho \[[@CR64]\]2016Primary ICHScoreDischargeAge, creatinine, NIHSS, heart disease, gender, and systolic blood pressure.0·870 (0·018) Huang \[[@CR40]\]2008Spontaneous medically treated ICH in hemodialysis patientsScore30 daysGCS, age, and systolic blood pressure.0·745 (0·048) Li \[[@CR50]\]2012Spontaneous ICHEquationDischargeAge, GCS, glucose, and white blood cell count.0·923 (0·020) Li´ \[[@CR49]\]2011Primary ICHScoreDischargeAge, Glucose, LDH, and white blood cell count.0·745 (0·025) Lukic \[[@CR33]\]2012Primary supratentorial medically treated ICHEquationDischargeLevel of consciousness, GCS verbal response, age, gender, and pulse pressure.0·856 (0·018) Lukic´ \[[@CR26]\]2012Spontaneous supratentorial ICHANNDischargeAge, gender, pulse pressure, mean arterial pressure, GCS (E/V/M), and consciousness.0·883 (0.048) Lukic´´ \[[@CR26]\]2012Spontaneous supratentorial ICHEquationDischargeGCS, level of consciousness.0·819 (0·030) Masé \[[@CR27]\]1995Primary supratentorial medically treated ICHEquation30 daysGCS, IVH spread, and hematoma size.-- Parry-Jones \[[@CR53]\]2013Spontaneous ICHEquation30 daysAge, GCS, IVH extension, and hematoma volume.0·897 (0·010) Peng \[[@CR54]\]2010Spontaneous ICHRandom Forrest30 daysAge, gender, hypertension, diabetes, ischemic heart disease, previous stroke, anemia, dialysis dependency, GCS, systolic/diastolic/mean blood pressure, infratentorial bleed, site of ICH, ICH volume, IVH, pineal shift, hydrocephalus, hemoglobin, and glucose.0·870 (0·015) Peng´ \[[@CR54]\]2010Spontaneous ICHANN30 daysAge, gender, GCS, site of ICH, ICH volume, IVH, hypertension, diabetes, anemia, and previous stroke.0·810 (0·020) Peng´´ \[[@CR54]\]2010Spontaneous ICHSVM30 daysAge, gender, GCS, site, ICH volume, IVH, hypertension, diabetes, anemia, and previous stroke.0·790 (0·020) Peng´´´ \[[@CR54]\]2010Spontaneous ICHEquation30 daysAnemia, age, GCS, hypertension, and dialysis dependency.0·780 (0·020) Romano \[[@CR56]\]2009Primary ICHScore30 daysGCS, hematoma volume, and intraventricular spread.0·915 (0·026) Ruiz-Sandoval \[[@CR58]\]2007Primary ICHScoreDischargeAge, infratentorial bleed, ICH size, GCS, and IVH spread.0·880 (0·017) Safatli \[[@CR60]\]2016Primary ICHScore30 daysGCS, infratentorial bleed, and hematoma volume.-- Szepesi \[[@CR32]\]2015Supratentorial ICHEquation30 daysAge, hematoma volume, IVH, systolic blood pressure, glucose, and potassium.-- Tabak \[[@CR59]\]2007Spontaneous ICHEquationDischargeAge, creatinine, glucose, pH, CO2, O2, partial thromboplastin time, prothrombin time, platelets, white blood cells, cancer, temperature, pulse, systolic blood pressure, respiratory rate, and altered mental status.0·890 (0·003) Takahashi \[[@CR67]\]2006Spontaneous ICHCARTDischargeJapan Coma Scale, ICH volume, and age.0·853 (0·024) Takahashi´ \[[@CR67]\]2006Spontaneous ICHEquationDischargeJapan Coma Scale, temperature, infratentorial bleed, and ICH volume.0·810 (0·033) Tshikwela \[[@CR36]\]2012Black hypertensive primary ICHScoreDischargeGCS, ICH volume, left hemisphere involved.-- Tshikwela´ \[[@CR36]\]2012Black hypertensive primary ICHScoreDischargeGender, GCS, midline shift.-- Tuhrim \[[@CR23]\]1999Primary supratentorial ICH managed medicallyEquation30 daysGCS, ICH volume, pulse pressure, hydrocephalus, and IVH volume.-- Tuhrim´ \[[@CR30]\]1991Supratentorial ICHEquation30 daysHematoma size, IVH, GCS, pulse pressure, and IVH^a^GCS interaction.0·900 (0·027) Tuhrim´´ \[[@CR29]\]1988Supratentorial hemorrhageEquation30 daysGCS score, hematoma size, and pulse pressure.0·892 (0·042) Ziai \[[@CR35]\]2015Primary ICH with IVHScoreDischargeTemperature, glucose, intracranial pressure, and Do-Not-Resuscitate orders0·850 (0·030) Zis \[[@CR39]\]2014Non-operated primary ICHScore30 daysGCS, ICH size, INR, IVH spread, and infratentorial location.0·920 (0·023)Functional outcome prediction tools Appelboom \[[@CR10]\]2012AVM related ICHScore3 monthsAge, IVH, infratentorial bleed, GCS, and hematoma size.0·914 (0·039) Creutzfeld \[[@CR47]\]2011Primary ICHEquationDischargeAge, GCS, heart rate, mass effect, IVH, premorbid level of function, and systolic blood pressure.0·930 (0·014) Flemming \[[@CR18]\]2001Lobar primary supratentorial ICHTree based modelDischargeGCS, septum pellucidum shift.0·890 (0·045) Flemming´ \[[@CR18]\]2001Lobar primary supratentorial ICHTree based modelDischargeICH size, GCS, and time to presentation.0·921 (0·032) Hallevy \[[@CR25]\]2002Primary supratentorial medically treated ICHScoreDischargeAge, limb paresis, level of consciousness, mass effect, hematoma size, and intraventricular extension.0·897 (0·023) Ji \[[@CR51]\]2013Spontaneous ICHScore1 yearAge, NIHSS, GCS, glucose, infratentorial bleed, ICH volume, and IVH.0·836 (0·009) Lisk \[[@CR22]\]1994Primary supratentorial \< 24 hEquationDischarge or 30 daysAge, GCS, hemorrhage volume, and gender.-- Lisk´ \[[@CR22]\]1994Primary supratentorial \< 24 h, GCS \> 9, no surgeryEquationDischarge or 30 daysAge, hemorrhage diameter, and ventricular extension.-- Neidert \[[@CR11]\]2016AVM related ICHScoreUnclearAge, GCS, hematoma size, IVH, AVM size, diffuse nidus, eloquence, and deep venous drainage.0·842 (0·046) Misra \[[@CR15]\]1999Primary putaminal ICHEquation3 monthsGCS, pupillary change, incontinence, and location of hematoma (cortical, subcortical, medial or lateral).-- Mittal \[[@CR52]\]2011Primary ICHScoreDischargeAge, infratentorial, ICH size, GCS, cognitive impairment, and FOUR score.-- Portenoy \[[@CR20]\]1987Nontraumatic supratentorial spontaneous ICHEquationUnclearGCS, ICH size (index), and IVH spread.-- Poungvarin \[[@CR55]\]2006Primary ICHEquationDischargeFever, ICH size \> 30, GCS, and IVH spread.-- Rost \[[@CR57]\]2008Primary ICHScore3 monthsAge, GCS, hematoma size, location (infratentorial/deep/lobar), and cognitive impairment.0·879 (0·017) Shah \[[@CR17]\]2005Thalamic hemorrhageEquation3 monthsPosterolateral ICH extension, Canadian Neurological Scale.-- Shaya \[[@CR19]\]2005Hypertensive supratentorial ICHScore6 monthsFocal neurological deficit, hydrocephalus, ICH volume-- Weimar \[[@CR42]\]2009Patients included in ICH trialsEquation3 monthsAge, NIHSS, and level of consciousness.0·805 (0·020) Weimar´ \[[@CR37]\]2006Non-comatose ICH patientsEquation100 daysAge, NIHSS.0·861 (0·029) Weimar´´ \[[@CR43]\]2006Spontaneous ICHScore100 daysAge, NIHSS, and level of consciousness.0·913 (0·018)Combined outcome prediction tools Cheung \[[@CR46]\]2003Nontraumatic ICHScore30 daysIVH, subarachnoid extension, pulse pressure, NIHSS, and temperature.---- Cheung´ \[[@CR46]\]2003Nontraumatic ICHScore30 daysAge, IVH, infratentorial bleed, NIHSS, and hematoma size.---- Cho \[[@CR14]\]2008Basal ganglia hemorrhageScore6 monthsGCS, ICH volume, and IVH.0·897 (0·033)^b^Barthel 0·884^a^\
GOS 0·935^ac^ Godoy \[[@CR62]\]2006Primary ICHScore30 days^b^Age, GCS, Graeb score, ICH volume, and APACHE2 score comorbidities.0·878\
(0·028)^b^6 months^c^0.893 (0·025)^c^ Godoy´ \[[@CR62]\]2006Primary ICHScore30 days^b^Age, GCS, Graeb score, ICH volume, and APACHE2 score comorbidities.0·869 (0·029)^b^6 months^c^0·895 (0·024)^c^ Lei \[[@CR13]\]2016Cerebral amyloid related ICHScore3 monthsAge, IVH, midline shift, and GCS.0·890\
(0·038)^b^0·810 (0·031)^c^ Stein \[[@CR16]\]2010Supratentorial deep ICH with secondary IVHScore30 days^b^Age, GCS, hydrocephalus, and ICH volume0·890 (0.036)^b^6 months^c^0·848 (0·056)^c^*SE* standard error, *ICH* intracerebral hemorrhage, *IVH* intraventricular hemorrhage, *CT* computerized tomography, *GCS* Glasgow Coma Scale, *ANN* artificial neural networks, *CART* classification and regression tree, *SVM* support vector machine, *ICU* intensive care unit, *CV* cardiovascular, *NIHSS* National Institute of Health Stroke Scale, *LDH* lactate dehydrogenase, *INR* International normalized ratio, *AVM* arteriovenous malformation, *GOS* Glasgow Outcome Score^a^C-statistics were reported but standard errors were not reported, nor were the number of outcomes^b^Mortality^c^Functional outcome

Population, sampling and source of data {#Sec6}
---------------------------------------

The source population from which the patients were recruited for prognostic tool derivation consisted on primary/spontaneous ICH patients for all tools except two \[[@CR10], [@CR11]\], which focused on arteriovenous malformation related hemorrhages (Table [1](#Tab1){ref-type="table"}). However, several studies included further specifications for patient inclusion namely age \[[@CR12]\], cerebral amyloid related angiopathy \[[@CR13]\], deep location \[[@CR14]--[@CR17]\], lobar location \[[@CR18]\], supratentorial bleeds \[[@CR16], [@CR19]--[@CR33]\], presence of intraventricular hemorrhage \[[@CR16], [@CR34], [@CR35]\], African ethnicity \[[@CR36]\], non-comatose patients \[[@CR22], [@CR37]\], comatose patients \[[@CR38]\], medically treated patients \[[@CR22]--[@CR25], [@CR27], [@CR33], [@CR38]--[@CR40]\], surgically treated patients \[[@CR21]\], oral anticoagulant related bleeds \[[@CR41]\], hypertensive patients \[[@CR19], [@CR36]\], and dialysis patients \[[@CR40]\]. The majority of studies (*n* = 40) recruited patients from hospitals or emergency rooms \[[@CR10]--[@CR14], [@CR16]--[@CR22], [@CR26], [@CR29]--[@CR31], [@CR36], [@CR40]--[@CR61]\] but nine studies recruited patients from intensive care units \[[@CR24], [@CR28], [@CR32], [@CR33], [@CR35], [@CR38], [@CR62]--[@CR64]\], three studies recruited patients from stroke units \[[@CR34], [@CR37], [@CR65]\], six studies recruited patients from neurology/neurosurgery departments \[[@CR15], [@CR25], [@CR27], [@CR39], [@CR66], [@CR67]\], and one study recruited patients from both an intensive care unit and a stroke unit \[[@CR23]\]. Most prognostic tools were derived from cohort studies, with the exceptions being registries \[[@CR29], [@CR30], [@CR43], [@CR51], [@CR64]\], randomized clinical trial data \[[@CR14], [@CR42]\], case-control studies \[[@CR26]\], and administrative databases \[[@CR59]\]. Thirteen studies were multicentric \[[@CR13], [@CR24], [@CR29], [@CR30], [@CR35]--[@CR37], [@CR42], [@CR43], [@CR51], [@CR55], [@CR59], [@CR62]\], with two studies involving more than two countries \[[@CR42], [@CR55]\]. The sampling method was not reported or unclear for 18 studies \[[@CR12], [@CR15], [@CR17], [@CR21], [@CR23], [@CR24], [@CR26], [@CR29], [@CR30], [@CR32], [@CR36], [@CR42], [@CR54], [@CR61], [@CR63], [@CR66]--[@CR68]\], being consecutive for all others.

Outcome timing, definition and assessment {#Sec7}
-----------------------------------------

Of the 72 prognostic tools included in this review 46 focused on mortality \[[@CR12], [@CR21], [@CR23], [@CR24], [@CR26]--[@CR36], [@CR38]--[@CR41], [@CR44], [@CR45], [@CR48]--[@CR50], [@CR53], [@CR54], [@CR56], [@CR58]--[@CR61], [@CR63]--[@CR68]\], 19 focused on morbidity \[[@CR10], [@CR11], [@CR15], [@CR17]--[@CR20], [@CR22], [@CR25], [@CR37], [@CR42], [@CR43], [@CR47], [@CR51], [@CR52], [@CR55], [@CR57]\], and seven were derived for a combined outcome (mortality plus morbidity) \[[@CR13], [@CR14], [@CR16], [@CR46], [@CR62]\].

Mortality prediction was mostly attempted at hospital discharge or 1 month (Table [1](#Tab1){ref-type="table"}); exceptions to this rule were the studies by Grellier \[[@CR66]\], Celik \[[@CR68]\], Lei \[[@CR13]\], Cho \[[@CR14]\], and Galbois \[[@CR38]\], which analyzed death at 2 days, 10 days, 3 months, 6 months, and ICU discharge respectively. Interestingly, Galbois focused on brain death rather than the general concept of mortality used in other studies. Functional status prediction was more heterogeneous on the timing and method of assessment: ten tools attempted to predict functional status at discharge/ 1 month \[[@CR18], [@CR22], [@CR25], [@CR46], [@CR47], [@CR52], [@CR55]\], eight tools attempted to predict at 3 months \[[@CR10], [@CR13], [@CR15], [@CR17], [@CR37], [@CR42], [@CR43], [@CR57]\], five tools attempted to predict at 6 months \[[@CR14], [@CR16], [@CR19], [@CR62]\], and one tool attempted to predict at 1 year \[[@CR51]\]. The studies by Portenoy \[[@CR20]\] and Neidert \[[@CR11]\] were unclear about the time of outcome assessment. The instrument for functional outcome evaluation also differed between studies: ten studies used the modified Rankin scale \[[@CR10], [@CR11], [@CR13], [@CR16], [@CR22], [@CR25], [@CR46], [@CR47], [@CR51], [@CR55]\], six studies used the Glasgow Outcome scale \[[@CR14], [@CR18], [@CR19], [@CR52], [@CR57], [@CR62]\], six studies used the Barthel index \[[@CR14], [@CR15], [@CR17], [@CR37], [@CR42], [@CR43]\], and one study used a subjective assessment \[[@CR20]\]. Only six studies reported blinded outcome assessment \[[@CR10], [@CR13], [@CR37], [@CR43], [@CR51], [@CR52]\]. All outcomes were binary except in the study by Shaya \[[@CR19]\], where the outcome was ordinal.

Number and type of predictors {#Sec8}
-----------------------------

The number of predictors for each prognostic tool ranged from two to 20, with the mode being three (Table [2](#Tab2){ref-type="table"}). The five most frequently included predictors were consciousness (*n* = 57), hematoma size (*n* = 43), age (*n* = 38), intraventricular blood (*n* = 32), and the presence of comorbidities (*n* = 16). Figure [2](#Fig2){ref-type="fig"} stratifies the ten most frequently used variables for mortality and functional outcome prediction.Table 2summary description of the tool development process and risk of biasAuthorSource of dataSampling reportedNr patientsNr eventsNr variableEPVLoss to follow-up:Missing data reported?Blinding reported?Modelling methodInternal validationCalibrationAlsina \[[@CR24]\]CohortNot reported10038312.70%YesNoLogisticNoHosmer-LemeshowBerwaerts \[[@CR41]\]CohortConsecutive4218290%YesNoLogisticNoNot reportedBhatia \[[@CR65]\]CohortConsecutive21470417.50%NoNoLogisticNoNot reportedBroderick \[[@CR44]\]CohortConsecutive16283219.80.6%YesNoLogisticNoNot reportedBroderick´ \[[@CR44]\]CohortConsecutive16283439.50.6%YesNoLogisticNoNot reportedCelik \[[@CR68]\]CohortNot reported257119129.90%NoNoANNCross-validationNot reportedCerillo \[[@CR21]\]CohortNot reported883474.90%NoNoUnivariate analysisNoNot reportedChen \[[@CR45]\]CohortConsecutive28561415.30%NoNoLogisticNoNot reportedChiu \[[@CR61]\]CohortNot reported10616280%YesNoCART + SVMSplit sampleNot reportedChuang \[[@CR63]\]CohortNot reported29340580%NoNoLogisticCross-validationHosmer-LemeshowEdwards \[[@CR28]\]CohortConsecutive8121151.40%NoNoANNNoHosmer-LemeshowEdwards´ \[[@CR28]\]CohortConsecutive812145.30%YesNoLogisticNoHosmer-LemeshowFogelholm \[[@CR31]\]CohortConsecutive2821206200%YesNoLogisticNoNot reportedFrithz \[[@CR12]\]CohortNot reported9179260%YesNoCARTNoNot reportedGalbois \[[@CR38]\]CohortConsecutive7235217.50%YesNoLogisticCross-validationNot reportedGalbois´ \[[@CR38]\]CohortConsecutive7235217.50%YesNoLogisticCross-validationNot reportedGrellier \[[@CR66]\]CohortNot reported300Not reported9n/a0%NoNoUnclearNoNot reportedHallevi \[[@CR34]\]CohortConsecutive174Not reported2n/a0%YesNoLogisticNoNot reportedHemphill \[[@CR48]\]CohortConsecutive15268513.60%YesNoLogisticNoNot reportedHo \[[@CR64]\]RegistryConsecutive805164627.30%NoNoLogisticNoLe Cessie and Howelingen + plotsHuang \[[@CR40]\]CohortConsecutive10772311.70%YesNoLogisticNoNot reportedLi \[[@CR50]\]CohortConsecutive22749412.30%YesNoLogisticNoNot reportedLi´ \[[@CR49]\]CohortConsecutive7161404350%YesNoLogisticNoNot reportedLukic \[[@CR33]\]CohortConsecutive4112565310%YesNoLogisticNoHosmer-LemeshowLukic´ \[[@CR26]\]Case-ControlNot reported200100812.50%YesNoANNSplit SampleNot reportedLukic´´ \[[@CR26]\]Case-ControlNot reported2001002500%YesNoLogisticNoNot reportedMasé \[[@CR27]\]CohortConsecutive13838312.70%NoNoLogisticNoNot reportedParry-Jones \[[@CR53]\]CohortConsecutive11754834120.81.1%YesNoLogisticNoNot reportedPeng \[[@CR54]\]CohortNot reported42362203.10%YesNoRandom ForrestCross-validationNot reportedPeng´ \[[@CR54]\]CohortNot reported42362106.20%YesNoANNCross-validationNot reportedPeng´´ \[[@CR54]\]CohortNot reported423621012.40%YesNoSVMCross-validationNot reportedPeng´´´ \[[@CR54]\]CohortNot reported42362512.40%YesNoLogisticCross-validationNot reportedRomano \[[@CR56]\]CohortConsecutive154633210.6%YesNoLogisticSplit sampleNot reportedRuiz-Sandoval \[[@CR58]\]CohortConsecutive378174534.80%YesNoLogisticBootstrapHosmer-LemeshowSafatli \[[@CR60]\]CohortConsecutive34286328.70%NoNoLogisticNoHosmer-LemeshowSzepesi \[[@CR32]\]CohortNot reported1255969.80%YesNoLogisticNoHosmer-LemeshowTabak \[[@CR59]\]Administrative dataConsecutive29,975676517397.90%YesNoLogisticBootstrapCalibration plotTakahashi \[[@CR67]\]CohortNot reported34770323.30%NoNoCARTCross-validationNot reportedTakahashi´ \[[@CR67]\]CohortNot reported34770417.50%NoNoLogisticNoNot reportedTshikwela \[[@CR36]\]CohortNot reported18568322.70%NoNoLogisticNoNot reportedTshikwela´ \[[@CR36]\]CohortNot reported18568322.70%NoNoLogisticNoNot reportedTuhrim \[[@CR23]\]CohortNot reported1292755.40%NoNoLogisticNoNot reportedTuhrim´ \[[@CR30]\]RegistryNot reported18754510.82.1%YesNoLogisticNoNot reportedTuhrim´´ \[[@CR29]\]RegistryNot reported732538.30%YesNoLogisticNoNot reportedZiai \[[@CR35]\]CohortConsecutive17087420.80%YesNoLogisticCross-validationNot reportedZis \[[@CR39]\]CohortConsecutive19161512.20%NoNoLogisticNoHosmer-LemeshowAppelboom \[[@CR10]\]CohortConsecutive841853.6UnclearYesYesLogistic (Update)NoNot reportedCreutzfeld \[[@CR47]\]CohortConsecutive424187726.70%NoNoLogisticNoHosmer-LemeshowFlemming \[[@CR18]\]CohortConsecutive81242120%YesNoDecision TreeNoNot reportedFlemming´ \[[@CR18]\]CohortConsecutive81513100%YesNoDecision TreeNoNot reportedHallevy \[[@CR25]\]CohortConsecutive18470611.70%NoNoLogisticNoNot reportedJi \[[@CR51]\]RegistryConsecutive19539127130.312.6%YesYesLogisticSplit sampleHosmer-LemeshowLisk \[[@CR22]\]CohortConsecutive753548.80%YesNoLogisticNoHosmer-LemeshowLisk´ \[[@CR22]\]CohortConsecutive429330%YesNoLogisticNoHosmer-LemeshowNeidert \[[@CR11]\]CohortConsecutive672883.50%NoNoUnivariate analysisNoNot reportedMisra \[[@CR15]\]CohortNot reported38Not reported4n/aUnclearYesNoLogisticNoNot reportedMittal \[[@CR52]\]CohortConsecutive9262560%NoYesLogistic (update)NoNot reportedPortenoy \[[@CR20]\]CohortConsecutive11241313.70%NoNoLogisticNoHosmer-LemeshowPoungvarin \[[@CR55]\]CohortConsecutive9954024100.50%YesNoLogisticNoNot reportedRost \[[@CR57]\]CohortConsecutive418121524.213.4%YesNoLogisticSplit sampleNot reportedShah \[[@CR17]\]CohortNot reported53292120%NoNoLogisticNoNot reportedShaya \[[@CR19]\]CohortConsecutive50n/a3n/a0%NoNoOrdered logisticNoNot reportedWeimar \[[@CR42]\]RCTsNot reported5641713570%YesNoLogistic (update)NoCalibration plotWeimar´ \[[@CR37]\]CohortConsecutive2077823920.4%YesYesLogisticNoNot reportedWeimar´´ \[[@CR43]\]RegistryConsecutive34089329.727%YesYesLogistic (update)NoNot reportedCheung \[[@CR46]\]CohortConsecutive14131^a^56.2^a^0.7%YesNoLogisticNoNot reported49^b^9.8^b^Cheung´ \[[@CR46]\]CohortConsecutive14131^a^56.2^a^0.7%YesNoLogistic (update)NoNot reported49^b^9.8^b^Cho \[[@CR14]\]RCTConsecutive22642^a^314^a^0%YesNoLogisticNoNot reportedUnclear^b^n/a^b^Godoy \[[@CR62]\]CohortConsecutive15353^a^510.6^a^0%YesNoLogistic (update)NoNot reported59^b^11.8^b^Godoy´ \[[@CR62]\]CohortConsecutive15353^a^510.6^a^0%YesNoLogistic (update)NoNot reported59^b^11.8^b^Lei \[[@CR13]\]CohortConsecutive17043^a^410.8^a^0%NoYesLogisticSplit sampleNot reported90^b^20^b^Stein \[[@CR16]\]CohortConsecutive11031^a^47.8^a^0%YesNoLogisticSplit sampleNot reported86^b^4.5^b^*ANN* artificial neural networks, *CART* classification and regression tree, *SVM* support vector machine^a^Values relating to mortality^b^Values relating to functional outcomeFig. 2Predictor distribution according to mortality vs functional outcome prediction tool

Number of patients and events {#Sec9}
-----------------------------

The number of included patients varied between 38 \[[@CR15]\] and 29,775 \[[@CR59]\] and the number of outcomes ranged from 9 \[[@CR22]\] to 6765 \[[@CR59]\] (Table [2](#Tab2){ref-type="table"}), with four studies not reporting this item \[[@CR14], [@CR15], [@CR34], [@CR66]\]. The event per variable (EPV) rate ranged from 1.4 \[[@CR28]\] to 398 \[[@CR59]\], with 21 derivations showing a rate \< 10 \[[@CR10]--[@CR12], [@CR16], [@CR21]--[@CR23], [@CR28], [@CR29], [@CR32], [@CR41], [@CR46], [@CR52], [@CR54], [@CR61], [@CR63], [@CR68]\].

Handling of missing data and loss to follow-up {#Sec10}
----------------------------------------------

Handling of missing data was not reported or unclear in 22 studies \[[@CR11], [@CR13], [@CR17], [@CR19]--[@CR21], [@CR23], [@CR25], [@CR27], [@CR28], [@CR36], [@CR39], [@CR45], [@CR47], [@CR52], [@CR60], [@CR63]--[@CR68]\] (Table [2](#Tab2){ref-type="table"}). Among studies reporting this item, all of them except two used a complete case analysis, with the exceptions using a missing cathegory \[[@CR37], [@CR59]\]. Two studies failed to report the number of patients lost to follow-up \[[@CR10], [@CR15]\]: as for the others, the majority of them showed a 100% complete follow-up but five studies showed a loss \< 5% \[[@CR30], [@CR44], [@CR46], [@CR53], [@CR56]\], two studies showed a loss of 5--20% \[[@CR51], [@CR57]\] and two studies showed a loss \> 20% \[[@CR37], [@CR43]\].

Methods used for tool derivation {#Sec11}
--------------------------------

Amongst the 72 prognostic tools encountered, 58 were regression based \[[@CR10], [@CR13]--[@CR17], [@CR19], [@CR20], [@CR22]--[@CR60], [@CR62]--[@CR65], [@CR67]\], 11 were machine learning algorithms \[[@CR12], [@CR18], [@CR26], [@CR28], [@CR54], [@CR61], [@CR67], [@CR68]\], two were based on univariate analysis \[[@CR11], [@CR21]\], and one was unclear on the method of derivation \[[@CR66]\] (Table [2](#Tab2){ref-type="table"}). Within the regression based tools, 51 were newly derived \[[@CR13]--[@CR17], [@CR19], [@CR20], [@CR22]--[@CR41], [@CR44]--[@CR51], [@CR53]--[@CR60], [@CR63]--[@CR65], [@CR67]\] and seven were model updates \[[@CR10], [@CR42], [@CR43], [@CR46], [@CR52], [@CR62]\]. Newly derived models preferentially used automated methods (forward/backward stepwise) for predictor selection during multivariate modelling (reported in 30 derivation procedures \[[@CR14]--[@CR17], [@CR19], [@CR20], [@CR22], [@CR23], [@CR25], [@CR26], [@CR28]--[@CR31], [@CR33], [@CR35]--[@CR37], [@CR40], [@CR41], [@CR44], [@CR46], [@CR48], [@CR49], [@CR51], [@CR54], [@CR56], [@CR63]--[@CR65]\]), whereas the method was unclear for ten \[[@CR13], [@CR24], [@CR32], [@CR38], [@CR45], [@CR55], [@CR57], [@CR58], [@CR60]\]. Model updates consisted in intercept recalibrations \[[@CR42]\], modifications of cut-off levels for specific variables \[[@CR10]\], and removal or introduction of new variables \[[@CR43], [@CR46], [@CR52], [@CR62]\]. Of the 58 regression based tools found, more than half (32) were presented as scores \[[@CR10], [@CR11], [@CR13], [@CR14], [@CR16], [@CR19], [@CR25], [@CR34]--[@CR36], [@CR38]--[@CR40], [@CR43], [@CR45], [@CR46], [@CR48], [@CR49], [@CR51], [@CR52], [@CR56]--[@CR58], [@CR60], [@CR62]--[@CR64], [@CR66]\]. Machine learning methods employed were artificial neural networks used in four tools \[[@CR26], [@CR28], [@CR54], [@CR68]\], decision trees used in four tools \[[@CR12], [@CR18], [@CR67]\], support vector machine used in one tool \[[@CR54]\], random forests used in one tool \[[@CR54]\], and a hybrid approach (decision tree + support vector machine) also used in one tool \[[@CR61]\] (Table [1](#Tab1){ref-type="table"}). Internal validation methods were used in 19 derivations: bootstrapping was used in two \[[@CR58], [@CR59]\], cross-validation was used in ten \[[@CR35], [@CR38], [@CR54], [@CR63], [@CR67], [@CR68]\] and split sample was used in seven \[[@CR13], [@CR16], [@CR26], [@CR51], [@CR56], [@CR57], [@CR61]\].

Prognostic tool performance {#Sec12}
---------------------------

C-statistics and respective 95% confidence intervals were retrieved from 38 mortality prediction tools and 15 functional outcome prediction tools (Table [1](#Tab1){ref-type="table"}). Forest plots are depicted in Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}. The lowest reported value was 0.745 \[[@CR49]\] and the highest reported value was 0.984 \[[@CR28]\]. Table [3](#Tab3){ref-type="table"} depicts robust variance estimates of pooled c-statistics for all tools combined and subgroup analysis for mortality prediction tools, functional outcome prediction tools, logistic regression based tools, and machine learning algorithms, along with comparisons using metaregression. All subgroups showed values for pooled c statistics \> 0.80. Mortality prediction tools and machine learning algorithms showed higher pooled AUCs but the differences were not statistically significant. Other measures of discrimination reported include accuracy, reported for 22 tools \[[@CR20], [@CR24], [@CR26]--[@CR30], [@CR33], [@CR37], [@CR40]--[@CR42], [@CR54]--[@CR56], [@CR63], [@CR68]\], sensitivity and/or specificity, reported for 31 tools \[[@CR10], [@CR14], [@CR16], [@CR22], [@CR24], [@CR31], [@CR34], [@CR38], [@CR39], [@CR41], [@CR43], [@CR44], [@CR46], [@CR49]--[@CR51], [@CR54]--[@CR56], [@CR58], [@CR62], [@CR63], [@CR68]\], and predictive values, reported for 22 tools \[[@CR10], [@CR14], [@CR31], [@CR38], [@CR41], [@CR43], [@CR44], [@CR46], [@CR51], [@CR52], [@CR54], [@CR56], [@CR58], [@CR62], [@CR63]\]. Calibration assessment was reported using a calibration plot for three derivations \[[@CR42], [@CR59], [@CR64]\], the Hosmer-Lemeshow test for 14 derivations \[[@CR20], [@CR22], [@CR24], [@CR28], [@CR32], [@CR33], [@CR39], [@CR47], [@CR51], [@CR58], [@CR60], [@CR63]\] and the Le Cessie and Howelingen test reported for one derivation \[[@CR64]\].Fig. 3Forrest plot of reported c statistics for mortality prediction toolsFig. 4Forrest plot of reported c statistics for functional outcome prediction toolsTable 3RVE pooled c statistics and subgroup comparisons using metaregressionPrognostic toolsNr studiesNr toolsPooled c-stat95%CII^2^ß95%CIpLowerUpperLowerUpperOverall40530·8780·8640·89179%--------Mortality prediction tools30380·8800·8650·89480%-0·007^a^-0·039^a^0·026^a^0·679Functional outcome prediction tools13150·8720·8420·90177%Logistic regression based tools37430·8740·8580·88976%0·018^b^-0·034^b^0·070^b^0·490Machine learning algorithms690·8980·8210·97688%^a^mortality prediction tools as reference group^b^logistic regression based tools as reference group

Discussion {#Sec13}
==========

Prognostic models for ICH patients have demonstrated good discrimination in derivation studies, regardless of the outcome in question (mortality or functional outcome). These tools have been derived in different ICH populations, ranging from "general" ICH (i.e. primary or spontaneous) to more specific populations (ex. arteriovenous malformation related bleeds, dialysis patients, comatose patients). Cohort studies are the predominant study design: this design is well suited for prognostic tool derivations due to an optimal measurement of predictors and outcome \[[@CR69]\]. Other sources of data used included registries, case-control studies, randomized clinical trial data and administrative databases. Of these, the last two raise concerns about representativeness and quality of data: on one side, clinical trials usually have the highest quality of data, but restrictive inclusion and exclusion criteria might hamper generalizability \[[@CR70]\]; on the other side, administrative databases might allow for easy access to a large quantity of patient data, but they are prone to errors in codification, data discrepancy, and missing data \[[@CR71]\]. A considerable number of studies (*n* = 11) were multicentric, conceding a theoretical advantage in terms of generalizability. The sampling method was frequently not reported (*n* = 15) but was consecutive for most studies, again assuring the representativeness of the population and minimizing in a convenient manner the risk of bias due to selective sampling.

Most mortality prediction tools focused on death at discharge or 1 month: this timing seems appropriate, since most deaths due to ICH occur early in the disease \[[@CR1]\]. However, the same cannot be said for functional outcome prediction: significant changes in functional status have been described in ICH patients up to 1 year \[[@CR72]\], rendering outcome predictions at 1 month or discharge less useful. Noticeably, 12 derivation procedures focused on functional outcome at discharge or 1 month. A reasonable compromise would be prediction at three to 6 months, allowing enough time for patient recovery without excessive loss to follow up or occurrence of competing events. Another important issue is that studies with longer follow-ups did not report on outpatient care interventions (ex. rehabilitation), making generalizability of their results less straightforward. Functional outcome prediction was mostly binary and used different scales and cut off values: whereas the optimal method of functional outcome measurement in ICH patients is debatable \[[@CR73]\], the usage of different scales and cut offs between tool derivation studies makes comparisons between these instruments more difficult. Only five studies reported blinded outcome assessment: whereas mortality is a rather "hard outcome", functional outcome evaluation is inherently more subjective and thus more prone to evaluation bias.

Derivation studies were rather heterogeneous in the number of patients and events analyzed. Interestingly, the four most frequently included variables for mortality prediction were also the four most frequently included variables for functional outcome prediction (Fig. [2](#Fig2){ref-type="fig"}). This overlap suggests that mortality prediction tools should, at least to some extent, predict functional outcome and vice-versa. The number of events per variable is a simple rule of thumb to assess the adequacy of sample size: it is suggested that a minimum of ten events per variable are required to prevent overfitting during statistical modelling \[[@CR73]\], but a lower rate was found for 21 tools, although admittedly not all of them were regression based.

Missing data, whether pertaining to missing predictors or loss to follow-up, is also a potential source of bias for derivation studies, with the risk of bias relating to the amount of missing data and the extent to which it is missing at random. Handling of missing predictors was frequently not reported (22 studies). Where it was reported, complete case-analysis was the method most frequently used, which potentially creates non-random, non-representative samples of the source population. For this purpose, guidelines for prediction modelling studies have suggested preferential use of other methods such as multiple imputation, noticing however that if the number of missing predictors is extensive this technique will not be sufficient to handle this problem \[[@CR69]\]. The same argument regarding risk of bias may be made for loss to follow-up: 4 studies reported a loss to follow-up \> 10%.

Discrimination and calibration are important properties for predictive models that should be reported. Discrimination relates to the extent to which a model distinguishes those who will suffer the outcome of interest from those who will not, whereas calibration refers to the agreement between observed and predicted outcome rates \[[@CR74]\]. C statistic is the most commonly used performance measure for discrimination \[[@CR75]\] but it was retrieved for only 38 derivations focusing on mortality and 15 derivations focusing on functional outcome. Taken together, these studies demonstrated good discriminatory ability for both predictions. The pooled C statistic for mortality prediction was 0.880 and the pooled C statistic for functional outcome prediction was 0.872 but these results must be interpreted with caution, due to the heterogeneity in the included studies in terms of population studied, selected predictors, method of model development and choice of outcome. Other forms of discriminatory ability reported include accuracy, sensitivity/specificity, and positive/negative predictive values, but the interpretation of these measurements is less straightforward: the first two require the use of cut-off points for predicted probabilities, therefore not allowing the full use of model information, whereas the last depend on the overall probability of the event in the studied sample, hampering extrapolations for other populations with different event rates. Calibration was only reported for 14 tools, either using the Hosmer-Lemeshow test, the Le Cessie and Howelingen test, or a calibration plot.

The most frequently used method for model derivation was logistic regression. There seems to be no consensus about the best method for variable selection during multivariate logistic regression modelling, but most studies used automatic methods. These methods allow for a more efficient use of data but come with an added risk of model overfit and possible exclusion of important predictor variables due to chance, especially when sample sizes are small \[[@CR76]\]. Nearly half of the regression based tools were simplified in the form of risk scores, allowing for an easier application. Machine learning algorithms found in our systematic review included decision trees (four), artificial neural networks (four), support vector machines (one), random forests (one) and a hybrid approach (one). These methods are an alternative to logistic regression that requires less formal statistical training and offer more efficient use of data and a higher ability to detect non-linear relations. However, they are prone to overfitting, extremely sensible to small perturbations in data and empirical in the nature of model development \[[@CR77], [@CR78]\]. Despite being pointed as more statistically efficient, these methods were not superior to logistic regression for discrimination in our review.

When models are tested in the same sample on which they were derived, their results tend to be biased due to overfitting: to minimize this problem, internal validation (resampling) techniques can be used. Only 19 derivations used resampling techniques for overfit adjustment. Bootstrapping is recommended as the preferred method of internal validation \[[@CR74]\], but was performed for only two. Other methods encountered included cross-validation and split sample. The later, used in three tools, is regarded as the least effective method since it reduces statistical power for the derivation procedure and does not validate the results in a new population.

In summary, the results from our review suggest that the most promising prognostic tools are i) logistic regression based risk scores, which combine the high discrimination showed by logistic regression with the ease of application typical of prognostic scores; ii) derived from general cohorts (i.e, spontaneous or primary ICH) to maximize generalizability; iii) without significant loss to follow up, to minimize risk of bias; iv) with early outcome measurement for mortality (i.e, discharge or 1 month) and later outcome measurement for functional outcome (i.e, 3 months or more) and v) showing high discrimination with an appropriate EPV rate. Examples of such scores include the scores by Chen \[[@CR45]\], Hemphill \[[@CR48]\], Ho \[[@CR64]\], Romano \[[@CR56]\] and Ruiz-Sandoval \[[@CR58]\] for mortality, Ji \[[@CR51]\] and Rost \[[@CR57]\] for functional outcome prediction and Godoy \[[@CR62]\] for a combined outcome. Not surprisingly, several validation studies have been published for these tools. Other factors to take into account are internal validation and blinded outcome assessment, the latter being particularly important for functional status.

Our review has limitations. Firstly, there were no clear guidelines on conducting and reporting studies for prognostic tool derivation at the time most of these studies were performed. This lead to frequent underreporting and higher difficulty in retrieving information about important methodological aspects and performance measures, which reflected on the results of our review. As an example, we were only able to retrieve c-statistics for 53 derivations, which means that several tools could not be evaluated for this important discrimination measure. Guidelines have recently been published to give guidance on this issue \[[@CR69]\]. Second, studies have demonstrated that healthcare professionals are frequently pessimistic in the face of neurological emergencies \[[@CR79]\]. This negative perception can result in a "self-fulfilling prophecy", whereby the physician's perception will lead to early withdrawal of care which, by itself, will facilitate a negative outcome \[[@CR79]\]. Most studies assessing the effect of early care limitation in the performance of prognostic models have focused on validation studies \[[@CR47], [@CR80], [@CR81]\]. According to these studies, models underestimate adverse outcomes in patients with early care limitation and overestimate in patients without. However, care limitation has also been demonstrated to be an independent predictor of poor outcome \[[@CR34], [@CR82]\]. Hence, one should expect that withdrawal of care would affect model performance also in derivation studies, but this factor was not taken in to account in the majority of studies included in this review. A possible solution for this problem is to derive prognostic models from patient populations with maximum level of care. Such approach was more recently used by Sembill and collaborators to derive the max-ICH score \[[@CR83]\]. Third, the previously discussed aspects of prognostic tool derivation are useful to assess the risk of bias and external validity of these instruments, but they do not necessarily determine the way these tools will behave in clinical practice. Risk of bias does not necessarily imply existing bias, and the ultimate issue is how they behave in an independent external dataset \[[@CR84]\]. At the time of our search we identified external validation studies for only 27 prognostic tools \[[@CR14], [@CR16], [@CR20], [@CR22], [@CR26], [@CR27], [@CR29]--[@CR31], [@CR37], [@CR40], [@CR41], [@CR43]--[@CR46], [@CR48], [@CR54], [@CR56]--[@CR59], [@CR62], [@CR63]\]. Nevertheless, derivation studies less prone to bias are more likely to perform well in validation studies. The issues discussed in this systematic review should then be taken as a guidance for future studies seeking to validate existing prognostic tools or to derive new ones in ICH patients as well as in other populations.

Conclusions {#Sec14}
===========

Prognostic models showed high discrimination in derivation studies for mortality and functional outcome prediction in ICH patients but numerous methodological and reporting deficiencies were present, namely insufficient length of follow-up for functional outcome, absence of blinding, reporting and handling of missing data, low EPV rate, infrequent use of appropriate internal validation procedures and underreporting of important model performance measures. Machine learning methods have not proven to be superior to regression based models and a significant number of these tools weren't submitted to external validation. Guidelines have been reported to support authors in developing and reporting studies both for prognostic model derivation and validation \[[@CR69]\].
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AUC

:   Area under the ROC curve

CI

:   Confidence interval

EPV

:   Event per variable

ICH

:   Intracerebral hemorrhage

ROC

:   Receiver operating characteristic

RVE

:   Robust variance estimation
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